Effect of Cocoa Flavanols on Vascular Function (Cocoa)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00553774 |
Recruitment Status :
Completed
First Posted : November 6, 2007
Last Update Posted : October 27, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Dietary Supplement: Cocoa Flavanols Other: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | Effect of Cocoa Flavanols on Vascular Function in Optimally Treated Coronary Artery Disease Patients: Interaction Between Endothelial Progenitor Cells, Reactivity of Micro- and Macrocirculation |
Study Start Date : | March 2007 |
Actual Primary Completion Date : | February 2008 |
Actual Study Completion Date : | February 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Flavanol
Cocoa Flavanol
|
Dietary Supplement: Cocoa Flavanols
Cocoa Flavanols (BD for 21 - 28 days) |
Placebo Comparator: Placebo |
Other: Placebo
Placebo (BD 21 - 28 Days) |
- An improvement of endothelial function as measured by flow-mediated dilation (FMD) [ Time Frame: 1 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- CAD patients over 18 years of age
- Contact university for more details.
Exclusion Criteria:
- Contact university for more details.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00553774
United States, California | |
University of California | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Yerem Yeghiazarians, MD | University of California, San Francisco |
Responsible Party: | Yerem Yeghiazarians, Proffessor of Clinical Medicine, University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00553774 |
Other Study ID Numbers: |
CHR#H47369-28112 |
First Posted: | November 6, 2007 Key Record Dates |
Last Update Posted: | October 27, 2016 |
Last Verified: | October 2016 |
CAD Patients on Optimal Treatment |
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |